Advanced search

Filters

Country

All countries

North America

South America

Europe

Africa

Middle East

Asia

Oceania

Central America

Select all

Capitalization

Sector

All sectors

  Energy

  Basic Materials

  Industrials

  Consumer Cyclicals

  Consumer Non-Cyclicals

  Financials

  Healthcare

  Technology

  Utilities

  Real Estate

  Institutions, Associations & Organizations

  Government Activity

  Academic & Educational Services

Select all

Add a keyword

Announcement Date

Since

Until

752 Results

Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Togo votes amid tensions over constitutional reform
RE
XOMA Corporation Announces Closing of Tender Offer
AQ
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
BU
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
GL
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
AQ
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories
AQ
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories
PR
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories
AQ
Pfizer : Oncology Innovation Day Presentation
PU
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology
BU
Atara Biotherapeutics, Inc. and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel®? Data in The Lancet Oncology
CI
Transcript : Elis SA, 2023 Sales/ Trading Statement Call, Jan 30, 2024
Transcript : Atara Biotherapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 09:45 AM
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
BU
Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer
GL
Acrivon Therapeutics, Inc. Announces Management Changes
CI
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories
BU
Atara Biotherapeutics, Inc. Announces Closing of Expanded Global Tab-Cel Partnership with Pierre Fabre Laboratories
CI
Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis
BU
Atara Biotherapeutics, Inc. Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis
CI
ATARA BIOTHERAPEUTICS ANNOUNCES EXPANDED GLOBAL TAB-CEL PARTNERSHIP WITH PIERRE FABRE LABORATORIES AND THIRD QUARTER 2023 FINANCIAL RESULTS
AQ
Transcript : Atara Biotherapeutics, Inc., Q3 2023 Earnings Call, Nov 01, 2023
Atara Biotherapeutics : Investor Presentation
PU
Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results
BU
Atara Biotherapeutics, Inc. Announces Expanded Global Tab-Cel Partnership with Pierre Fabre Laboratories
CI
Immutep : ESMO 2023 - EFTISARC-NEO Trial in Progress Poster (Soft Tissue Sarcoma)
PU
DBV Technologies S.A. Announces Executive Changes
CI
DBV Technologies S.A. Appoints Virginie Boucinha as Principal Accounting Officer, Effective as of November 6, 2023
CI
DBV Technologies appoints new CFO
CF
DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer
GL
U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
BU
U.S. FDA Approves Pfizer?s Braftovi® + Mektovi® for Braf V600e-Mutant Metastatic Non-Small Cell Lung Cancer
CI
Pierre Fabre Laboratories and Vernalis announce a drug discovery collaboration in oncology
AQ
ATARA BIOTHERAPEUTICS ANNOUNCES PLANS TO SUBMIT TAB-CEL BLA IN Q2 2024 FOLLOWING FDA AGREEMENT ON COMPARABILITY
AQ
Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on Comparability
BU
Transcript : Atara Biotherapeutics, Inc. Presents at Citi 18th Annual BioPharma Conference, Sep-07-2023 01:50 PM
Transcript : Gracell Biotechnologies Inc. Presents at Citi 18th Annual BioPharma Conference, Sep-07-2023 01:50 PM
Transcript : Cabaletta Bio, Inc. Presents at Citi 18th Annual BioPharma Conference, Sep-07-2023 01:50 PM
Atara Biotherapeutics : Investor Presentation
PU
Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress
BU
Transcript : ImmunoPrecise Antibodies Ltd., Q4 2023 Earnings Call, Jul 07, 2023
Transcript : Atara Biotherapeutics, Inc. Presents at Goldman Sachs 44th Annual Global Healthcare Conference, Jun-14-2023 04:00 PM
ATARA BIOTHERAPEUTICS PRESENTS UPDATED TAB-CEL CLINICAL EFFECTIVENESS DATA AT ASCO 2023
AQ
ASCO 2023 Annual Meeting: A Phase 1/2 Study of CFT1946 Trial-in-Progress Poster
PU
Atara Biotherapeutics Presents Updated Tab-cel® Clinical Effectiveness Data at ASCO 2023
BU
Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting
BU
ATARA BIOTHERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress
BU
Pfizer Inc - FDA Accepts Pfizer's Supplemental New Drug Applications for BRAFTOVI + MEKTOVI
AQ
FDA Accepts Pfizer’s Supplemental New Drug Applications for BRAFTOVI + MEKTOVI
BU
No results for this search
  1. Stock Market
  2. Advanced search
  3. Pierre Fabre
  4. News